Breakthrough T1D Launches Third Center of Excellence in New England
The Breakthrough T1D New England Center of Excellence will focus on protecting the stem cell-derived beta cells from rejection by the immune system after transplantation.
Vertex Has a New Horizon: Curing Type 1 Diabetes
Vertex Pharmaceuticals will launch a clinical trial of VX-880, a stem cell-derived beta cell therapy in type 1 diabetes (T1D).
Why Does One Scientist Seek to Find Cures for T1D? Answer: His Children
Douglas Melton, Ph.D., can now produce unlimited quantities of beta cells. He now wants to evade the immune attack. See our video to find out more.
Breakthrough T1D Video: “Wouldn’t Have Happened Without Breakthrough T1D”
Dr. Robert Langer co-founded Moderna, who gained emergency use approval for its COVID vaccine. Watch the video to find out how Breakthrough T1D is helping to advance his research.
Breakthrough T1D Video: Solving What Happens After Transplantation
Hear Dr. Elad Sintov talk about his research into beta cell replacement technology with our new video.
Making Beta Cells from Stem Cells Automated and Reproducible
With Breakthrough T1D support, ARMI is translating the Millman procedure into an automated process to generate an unlimited amount of stem cell-derived beta cells.
Robots! Compounds! Chemical Biology! Oh My!
Bridget Wagner, Ph.D., is a chemical biologist who wants to find a compound that can repopulate the beta cells that have been lost in type 1 diabetes (T1D).
Solving Big Challenges in Beta Cell Transplantation
You’re going to hear about a part of your body that, really, goes unnoticed in type 1 diabetes (T1D): blood vessels. But blood vessels are everywhere. From your eye to your lungs to even your pancreas. And they’re really, really important. Do you know that these vessels transport blood cells, nutrients and oxygen to all […]
Cell Therapy Approaches Moving Along the Pipeline
Beta cell replacement therapies for type 1 diabetes (T1D) have made significant advances in just the past 10 years. We now have insulin-producing beta cells, derived from stem cells, which makes a donor (needed to provide the beta cells) obsolete. We have seen that stem cell-derived precursors can—once implanted in humans—mature into beta cells and […]
Viacyte Receives Funding to Continue Developing Beta Cell Therapies
ViaCyte, a regenerative medicine company long-supported by Breakthrough T1D, today announced $27 million in financing to continue the development of beta cell therapies for diabetes. This funding ensures that Viacyte’s innovative approaches to replacing the insulin-producing beta cells in people with type 1 diabetes (T1D) will keep progressing. “Beta cell therapies are a key component […]
